Beijing medical insurance drugs into the information bank management will set off an irreversible impact on national prices.

On August 12, the Beijing Municipal Health Insurance Bureau and the Beijing Municipal Medical Insurance Center announced the Notice (Trial) on issues related to the issuance of the beijing Basic Medical Insurance Work Injury Insurance and Maternity Insurance Drug Filing Work. The
Notice provides in detail for the filing principle, "Where the generic name and dosage form belong to the beijing basic medical insurance work injury insurance and maternity insurance drug reimbursement scope of different specifications, packaging, production enterprises of Western medicine, traditional Chinese medicine (including ethnic medicine), by the pharmaceutical production or wholesale operation enterprises to the Beijing Municipal Medical Insurance Affairs Management Center for the record, into the management of the drug information bank."
within the scope of Beijing Sunshine Procurement (including filing procurement) or the centralized procurement of the army, as well as psychosethic, anesthesia, medical toxicity, radioactivity and other specially administered drugs are filed. The
" section focuses on: "Providing false filing information, raise the purchase price without authorization, and other recorded drugs that seriously violate the regulations of the relevant departments of medical insurance, drug supervision, health, price, etc. will automatically disqualify the filing and be removed from the drug information bank."
" We are used to Fujian Province, Wuhan City and other places in the drug consumption recruitment to play a front wave, although Beijing has long been listed in the drug belt procurement "4 plus 7" and consumables centralized procurement "3 plus 6", in fact, has been very low-key.
this time to all health insurance drugs into the information bank management, can be described as a pioneering, play a reform exploration.
the sheer reach and determination of its actions gave us a presesset that the landscape would change.
Health insurance drugs are all included in the information bank management is not fine management August 14, the State Health Insurance Administration issued the first batch of 3 health insurance management efficiency cases, including the "Hebei standardized provincial medical institutions drug procurement behavior" case, Hebei Provincial Health Insurance Bureau from 11 hospitals in the province to rectify the regulation of 432 drugs procurement behavior, is expected to save more than 90 million yuan a year procurement funds.
Carefully compare the separate practices of Beijing and Hebei Province, we believe that: Hebei Province's health insurance management efficiency cases have been reflected in the short term, but long-term adherence to effectiveness, cycle retention efficiency, there are still a lot of variables, need to further comb to form a long-term mechanism.
Beijing will be all medical insurance drugs into the information bank management, although not from the drug control fees, the future is not good statistics, but the starting point sealed the principle, help long-term implementation.
this practice in Beijing is not fine management, but must be principle management, this kind of bottom-level, system design is very life-threatening.
regarding the unauthorized increase in procurement prices will be directly deleted by the drug information base To clarify one thing: Beijing's inclusion of all medical insurance drugs in the information bank management mentioned in the record, and the record procurement is a downright different matter.
Since it is necessary to emphasize specifically that no unauthorized increase in procurement prices is allowed, that is to say, before and even at present in the online procurement, record procurement, centralized procurement exists, need to be subject to principle.
We are mainly concerned about three things: First, before and even now, some pharmaceutical companies arbitrarily subjective price increases, that can not stop the hospital attachment and purchase, the future of pharmaceutical companies have disciplinary measures, hospitals should also strengthen reporting requirements, not reporting, that is, accountability.
, pharmaceutical companies have the right to raise prices, how can we say that the price increase is unauthorized? For the drug purchased by hanging network, when in the purchase and sale contract privately granted, learn real estate transaction Yin and Yang contract that set, and happen to have a price gap, then sit on the unauthorized price increase.
sunshine procurement must ensure sunshine.
Third, pharmaceutical companies have the right to raise prices, if the online procurement in the public increase in pricing, or in the record procurement in a fair and earthly increase in pricing, it does not seem to be unauthorized price increases.
buyers of health insurance are either complying with drug companies' demands for higher prices or simply deleting the drug information bank.
To the 3d option, local Medicare buyers need to be proactive and responsive, find local alternative similar medicines immediately for price increases, or urgently transfer the same or similar drugs from abroad that have not yet increased their prices.
we think the feasibility is still very big, after all, any pharmaceutical companies in one place to raise prices is not difficult, difficult is the national price increase, that is not what death.
the implementation of this system in Beijing has given birth to important changes both locally and throughout the country First, the price of medical insurance drugs in Beijing has a certain impact on the national reference pricing.
and present, some pharmaceutical companies in the actual purchase price is higher, the future will be greatly restricted by this system.
need to be explained that this phenomenon is located at a relatively low level, generally pharmaceutical marketing and hospital a family to talk about, is already a mess, should also be blocked.
We are concerned that in the future, after the system came into effect, some pharmaceutical companies will deliberately set the price of the Beijing medical insurance drugs they supply higher, and in the hospital procurement at the actual lower prices, so that the drilling policy may be more harmful.
because it seriously fooled the Beijing medical insurance drug prices as a reference for pricing of foreign medical insurance drug procurement platform and competing enterprises.
Preventive measures is to seriously promote the provincial drug centralized procurement of the lowest price linkage mechanism, pharmaceutical enterprises are difficult to set high prices in the country as a breakthrough, in the local special promotion of drug belt procurement, negotiations outside the drug price management, actively explore the linkage of the provincial minimum price mechanism and methods, and strive for inaction.
"'Medicare Drug Catalog' gives the generic name of the drug, and specific to a drug may have more than one pharmaceutical production enterprises can produce, when the drug enters the hospital will use the drug commodity name.
In this way, before medical insurance reimbursement, each pharmaceutical production enterprise needs to file a record with the relevant departments, and record in detail the generic name, commodity name, dosage form, drug instructions adaptation, usage and drug production enterprises.
" Second, the Beijing Health Insurance Drug Information Bank will reshape the local medical insurance drug market.
is the purchase price of drugs, depending on the policy of zero-plus-rates of drugs, social supervision of drug prices more convenient.
, such as any change in the price of medical insurance drugs, is known both by the hospital procurement chain and by the clinical sales chain.
Second, in the comparison of drug selection, we look forward to different pharmaceutical products with the generic name in the medical insurance procurement platform, hospital sales terminal on the head of the same generic name and different commodity names, to facilitate the two sides of the doctor and patient know, medical insurance information management, drug industry supervision.
3. In the distribution and use of drugs, it is suggested that the access and procurement requirements of medical insurance drugs should be put forward to the fixed-point hospitals of various levels of medical insurance, making full use of the access law and exclusion method, realizing the guarantee of the supply of basic drugs in primary health care institutions, and the requirements of drug economics for the use of special drugs in higher-grade hospitals.
this kind of mechanism belongs to the fine management of medical insurance.
.